All In Biotech

Drug Trial Radar · NCT07097831

A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects

An Open-label, Single-arm, Fixed-sequence, Single-center Phase I Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 9, 2025

Primary completion

Nov 7, 2025

Study completion Nov 7, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study was designed to evaluate the pharmacokinetic effects of rosuvastatin calcium tablets after oral administration of HRS-1301 in healthy subjects.

Conditions

  • Hyperlipidemia

Interventions

  • HRS-1301 TabletsDrug

    HRS-1301 tablets.

  • Rosuvastatin Calcium TabletsDrug

    Rosuvastatin calcium tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve from time 0 to time t (AUC0-t)Time frame: 0 to anticipated 15 days.
  2. Area under the curve from time 0 to time infinity (AUC0-∞)Time frame: 0 to anticipated 15 days.
  3. Maximum concentration (Cmax)Time frame: 0 to anticipated 15 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.